Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment

AIDS

Volumn 17, Issue 15, 2003, Pages 2209-2214

  De Maat, Monique M R ^a   Ter Heine, Rob ^a   Van Gorp, Eric C M ^a   Mulder, Jan W ^a   Mairuhu, Albert T A ^a   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acute clinical hepatitis; Nevirapine; Patient characteristics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CETIRIZINE; NEVIRAPINE; PREDNISONE; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; EOSINOPHILIA; FATTY LIVER; FEMALE; HEPATOMEGALY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; MEDICAL RECORD; OUTPATIENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RNA, VIRAL; TRANSAMINASES;

EID: 0242333213     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200310170-00009     Document Type: Article

References (21)

1. Katlama C, Murphy R, Johnson V, Squires K, Horban A, Gatell J, et al. The Atlantic Study: A randomised open-label study comparing two protease inhibitors (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September, 1999 [abstract LB-22].
2. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez JL, Lozano L, et al. A randomized, open, multicenter trial comparing combivir plus nelfinavir or nevirapine in HIV-infected naive patients (The Combine Study). Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 327].
3. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, et al. Antiretroviral treatment simplication with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multi-center, randomized, controlled study. J Aquir Immune Defic Syndr 2001, 27:229-236.
4. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996, 5:1183-1199.
5. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998, 279:930-937.
6. Martinez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001, 15:1261-1268.
7. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999, 29:455-456.
8. Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000, 11:336-337.
9. Jarrousse B, Cohen O, Berlureau P, Bentata M, Mahr A, Guillevin L. Nevirapine induced fulminant hepatitis: presentation of case and analysis of risk factors. Seventh European Conference on Clinical Aspects and treatment of HIV-Infection. Lisbon, October 1999 [abstract 1009].
10. Mateu S, Gurgui M, Sambeat MA, Barrio JL, Fuster M, Llinares J, et al. Cholestatic hepatitis by nevirapine: report of five cases. Seventh European Conference on Clinical Aspects and treatment of HIV-Infection. Lisbon, October 1999 [abstract 1080].
11. Leitze Z, Nadeem A, Choudhary A, Saul Z, Roberts I, Manthous CA. Nevirapine-induced hepatitis treated with corticosteroids? AIDS, 12:1115-1117.
12. Fernandez-Guerrero ML, Becares J, Gorgolas M, Garcia-Delgado R. Nevirapine induced acute hepatitis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December, 2001 [abstract 1-209].
13. AIDS Clinical Trial Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and infectious Diseases; 1996.
14. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12: 1735-1744.
15. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 1997, 11:1294-1296.
16. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000, 33:192-196.
17. Bartlett J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 19].
18. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997, 349:995-996.
19. Dieterich D, Stern J, Robinson P, Hall D, Carlier H. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B & C seropositivity, and baseline liver function tests. First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 44].
20. Sulkowski M, Mehta S, Thomas D, Moore R. Hepatotoxicity associated with NNRTI use: Role of drugs and chronic viral hepatitis. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 618].
21. Martin-Carbonero L, Rodríguez-Rosado R, Soriano V, Gonzalez-Lahoz J. Hepatotoxicity of non nucleoside analogues: nevirapine vs efavirenz. Fifth International Congress on Drug Therapy in HIV Infection. Glasgow, October 2000 [abstract P164].